Tiago Fauth
Stock Analyst at Wells Fargo
(1.20)
# 3,336
Out of 4,814 analysts
136
Total ratings
30.77%
Success rate
-15.84%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $16.96 | +495.52% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $234.75 | +22.26% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.46 | +105.48% | 2 | Mar 4, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $74 → $93 | $58.69 | +58.46% | 4 | Feb 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $28 → $26 | $14.06 | +84.92% | 6 | Feb 27, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $17 | $6.83 | +149.08% | 1 | Feb 20, 2025 | |
| INSM Insmed | Maintains: Overweight | $85 → $107 | $72.47 | +47.65% | 3 | Feb 19, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $14 → $11 | $0.92 | +1,089.96% | 2 | Jan 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $35.64 | +146.91% | 7 | Dec 20, 2024 | |
| SVRA Savara | Initiates: Overweight | $8 | $3.01 | +166.22% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.54 | +98.46% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $68 | $47.45 | +43.31% | 1 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $5.92 | +271.62% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $42.24 | +77.56% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $380 | $284.73 | +33.46% | 4 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $35 → $2 | $2.77 | -27.80% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.08 | +5,667.44% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $160.53 | -44.56% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $13.10 | +289.31% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $59.12 | +102.98% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $15.15 | -73.59% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.10 | +351.61% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.12 | +3,152.03% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $5.88 | +342.18% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.42 | +1,059.42% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $18.17 | +345.79% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.32 | +2,383.70% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $0.96 | +1,351.23% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.56 | +5,971.43% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $2.43 | +6,072.84% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $36.06 | -19.58% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.80 | +622.22% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.29 | +911.67% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.06 | +88.68% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $593.60 | -42.72% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $277.29 | -6.60% | 1 | Apr 28, 2021 |
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $16.96
Upside: +495.52%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $234.75
Upside: +22.26%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.46
Upside: +105.48%
Verona Pharma
Feb 28, 2025
Maintains: Overweight
Price Target: $74 → $93
Current: $58.69
Upside: +58.46%
Keros Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $14.06
Upside: +84.92%
Amicus Therapeutics
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $6.83
Upside: +149.08%
Insmed
Feb 19, 2025
Maintains: Overweight
Price Target: $85 → $107
Current: $72.47
Upside: +47.65%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $14 → $11
Current: $0.92
Upside: +1,089.96%
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $35.64
Upside: +146.91%
Savara
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $3.01
Upside: +166.22%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $4.54
Upside: +98.46%
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $47.45
Upside: +43.31%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $5.92
Upside: +271.62%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $42.24
Upside: +77.56%
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $284.73
Upside: +33.46%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.77
Upside: -27.80%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.08
Upside: +5,667.44%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $160.53
Upside: -44.56%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $13.10
Upside: +289.31%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $59.12
Upside: +102.98%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $15.15
Upside: -73.59%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.10
Upside: +351.61%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.12
Upside: +3,152.03%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $5.88
Upside: +342.18%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.42
Upside: +1,059.42%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $18.17
Upside: +345.79%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.32
Upside: +2,383.70%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $0.96
Upside: +1,351.23%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.56
Upside: +5,971.43%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $2.43
Upside: +6,072.84%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $36.06
Upside: -19.58%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.80
Upside: +622.22%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.29
Upside: +911.67%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.06
Upside: +88.68%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $593.60
Upside: -42.72%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $277.29
Upside: -6.60%